Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1989;37(1):33-6.
doi: 10.1007/BF00609420.

Reduction of Postprandial Blood Glucose by the Alpha-Glucosidase Inhibitor Miglitol (BAY M 1099) in Type II Diabetes

Affiliations
Clinical Trial

Reduction of Postprandial Blood Glucose by the Alpha-Glucosidase Inhibitor Miglitol (BAY M 1099) in Type II Diabetes

G Heinz et al. Eur J Clin Pharmacol. .

Abstract

The dose-dependency of the effects of the alpha-glucosidase inhibitor Miglitol (Bay m 1099) was investigated in 8 Type II diabetic patients. Administration of increasing doses of Miglitol once daily in the morning on four consecutive days concomitantly with a standardized meal containing 50 g starch led to a dose-dependent reduction in the maximal increase in the postprandial blood glucose level and in postprandial incremental AUC of blood glucose. The latter was significant for 50, 100, 75 and 200 mg Miglitol. Bay m 1099 also markedly retarded the appearance of the peak postprandial blood glucose concentration, which indicates delayed carbohydrate absorption. Serum insulin levels, documented as incremental AUCs of the serum insulin excursions, were not reduced dose dependently, because of the impaired insulin secretory capacity of the patients.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Lancet. 1978 Dec 23-30;2(8104-5):1386 - PubMed
    1. Eur J Clin Pharmacol. 1987;31(6):723-4 - PubMed
    1. J Clin Endocrinol Metab. 1977 May;44(5):876-83 - PubMed
    1. Gut. 1986 Dec;27(12 ):1471-8 - PubMed
    1. Diabetologia. 1980;18(2):89-95 - PubMed

Publication types

LinkOut - more resources

Feedback